The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases

Murphy K, Weaver C. Janeway’s Immunobiology. 9th edition. Garland Science.

Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol. 1979;123:2928–9.

Nomenclature for secreted regulatory proteins of the immune system (interleukins). WHO-IUIS Nomenclature Subcommittee on Interleukin Designation. Bull World Health Organ. 1991;69:483–6.

Nomenclature for secreted regulatory proteins of the immune system (interleukins): update. IUIS/WHO Standing Committee on Interleukin Designation. Bull World Health Organ. 1997;75:175.

Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138:984–1010.

CAS  PubMed  Article  Google Scholar 

Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genom. 2010;5:30–55.

CAS  Article  Google Scholar 

Hymowitz SG, Filvaroff EH, Yin J, Lee J, Cai L, Risser P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332–41.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Coondoo A. Cytokines in dermatology—a basic overview. Indian J Dermatol. 2011;56:368–74.

PubMed  PubMed Central  Article  Google Scholar 

Dinarello CA. Historical review of cytokines. Eur J Immunol. 2007;37:S34-45.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jia H, Liu J, Han B. Reviews of interleukin-37: functions, receptors, and roles in diseases. BioMed Res Int. 2018;2018: e3058640.

Google Scholar 

Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member*. J Biol Chem. 2001;276:20597–602.

CAS  PubMed  Article  Google Scholar 

Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23:159–63.

CAS  PubMed  Article  Google Scholar 

Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–56.

CAS  PubMed  Article  Google Scholar 

Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7:231–40.

CAS  PubMed  Article  Google Scholar 

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.

CAS  PubMed  Article  Google Scholar 

Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20.

CAS  PubMed  Article  Google Scholar 

Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.

CAS  PubMed  Article  Google Scholar 

Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66–7.

PubMed  Article  Google Scholar 

Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.

PubMed  Article  Google Scholar 

Ganesan R, Raymond EL, Mennerich D, Woska JR, Caviness G, Grimaldi C, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs. 2017;9:1143–54.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tauber M, Viguier M, Le Gall C, Smahi A, Bachelez H. Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist? Br J Dermatol. 2014;170:1198–9.

CAS  PubMed  Article  Google Scholar 

Bachelez H, Choon S-E, Marrakchi S, Burden AD, Tsai T-F, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–3.

PubMed  Article  Google Scholar 

EMA validates spesolimab marketing authorization application in GPP | Press [Internet]. boehringer-ingelheim.com [cited 2021 Nov 14]. https://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab.

Reich A, Barker J, Pink A, Reynolds NJ, Griffiths CEM, Kalapanda R, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a phase 2 trial. 2021. p. 1–15.

Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. PNAS Natl Acad Sci. 1989;86:6367–71.

CAS  Article  Google Scholar 

Palmou-Fontana N, Gaviño JAS, McGonagle D, García-Martinez E, Martín LIO. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. DRM. 2014;228:311–3.

CAS  Google Scholar 

Laurent S, Le Parc J-M, Clérici T, Bréban M, Mahé E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163:1364–5.

CAS  PubMed  Article  Google Scholar 

Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol. 2012;39:657.

PubMed  Article  Google Scholar 

Fritz Y, Klenotic PA, Swindell WR, Yin ZQ, Groft SG, Zhang L, et al. Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO mice. J Invest Dermatol. 2017;137:696–705.

CAS  PubMed  Article  Google Scholar 

Blauvelt A. IL-6 differs from TNF-α: unpredicted clinical effects caused by IL-6 blockade in psoriasis. J Invest Dermatol. 2017;137:541–2.

CAS  PubMed  Article  Google Scholar 

Takematsu H, Tagami H. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Dermatol. 1993;129:74–80.

CAS  PubMed  Article  Google Scholar 

Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci. 2001;26:119–24.

CAS  PubMed  Article  Google Scholar 

Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527–37.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol. 2010;185:5688–91.

CAS  PubMed  Article  Google Scholar 

Kulig P, Musiol S, Freiberger SN, Schreiner B, Gyülveszi G, Russo G, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183:276–84.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551–60.

CAS  PubMed  Article  Google Scholar 

Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.

CAS  PubMed  Article  Google Scholar 

Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379–90.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol. 2008;181:5948–55.

CAS  PubMed  Article  Google Scholar 

Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186:1495–502.

CAS  PubMed  Article  Google Scholar 

Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142–52.

CAS  PubMed  Article  Google Scholar 

Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397:1564–75.

CAS  PubMed 

留言 (0)

沒有登入
gif